KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Tax Provisions (2016 - 2025)

NovoCure's Tax Provisions history spans 12 years, with the latest figure at -$16.5 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 253.56% year-over-year to -$16.5 million; the TTM value through Dec 2025 reached -$23000.0, down 100.06%, while the annual FY2025 figure was -$23000.0, 100.06% down from the prior year.
  • Tax Provisions for Q4 2025 was -$16.5 million at NovoCure, down from $7.2 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $10.7 million in Q4 2024 and bottomed at -$16.5 million in Q4 2025.
  • The 5-year median for Tax Provisions is $3.3 million (2022), against an average of $3.5 million.
  • The largest annual shift saw Tax Provisions surged 611.4% in 2024 before it plummeted 253.56% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $885000.0 in 2021, then surged by 436.16% to $4.7 million in 2022, then skyrocketed by 80.08% to $8.5 million in 2023, then grew by 25.41% to $10.7 million in 2024, then tumbled by 253.56% to -$16.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Tax Provisions are -$16.5 million (Q4 2025), $7.2 million (Q3 2025), and $5.2 million (Q2 2025).